In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia.
Saved in:
| Title: | In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia. |
|---|---|
| Authors: | Vafai SB; Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston., Täubel J; Richmond Pharmacology, London.; St. George's University of London, London., Ashdown T; Richmond Pharmacology, London., Patel RS; Institute of Cardiovascular Science, University College London, London.; Barts Health NHS Trust, London., Diamondali S; Barts Health NHS Trust, London., Cegla J; Imperial College London, London., Soran H; National Institute for Health and Care Research-Wellcome Trust Clinical Research Facility, Manchester University NHS Foundation Trust, Manchester, United Kingdom., Bashir B; National Institute for Health and Care Research-Wellcome Trust Clinical Research Facility, Manchester University NHS Foundation Trust, Manchester, United Kingdom., Abitbol A; LMC Diabetes and Endocrinology, Toronto.; Centricity Research, Toronto., Gaudet D; Department of Medicine, Université de Montréal, Montreal.; ECOGENE-21 Clinical Research Center, Chicoutimi, QC, Canada., Lauzière A; Department of Medicine, Université de Montréal, Montreal.; ECOGENE-21 Clinical Research Center, Chicoutimi, QC, Canada., Brunham LR; Department of Medicine, University of British Columbia, Vancouver, Canada.; Healthy Heart Program Prevention Clinic, St. Paul's Hospital, Vancouver, BC, Canada., Newby DE; British Heart Foundation Centre for Research Excellence, University of Edinburgh, Edinburgh., Nicholls SJ; Victorian Heart Institute, Monash University, Melbourne, VIC, Australia., Scott RS; New Zealand Clinical Research, Christchurch, New Zealand., Kerr J; New Zealand Clinical Research, Christchurch, New Zealand., Tardif JC; Montreal Heart Institute, Université de Montréal, Montreal., Lunken C; University College London Hospitals NHS Foundation Trust, London., Humphries SE; Institute of Cardiovascular Science, University College London, London., Karsten V; Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston., Tyler PD; Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston., Zhang X; Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston., Huniti N; Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston., Flight PA; Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston., Jensen CL; Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston., Falzone R; Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston., Biedenkapp JC; Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston., Lister T; Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston., Stolz LE; Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston., Khera AV; Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston., Kathiresan S; Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston. |
| Source: | The New England journal of medicine [N Engl J Med] 2026 May 25. Date of Electronic Publication: 2026 May 25. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1533-4406 (Electronic) Linking ISSN: 00284793 NLM ISO Abbreviation: N Engl J Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
